Phaseline

Companies › SystImmune

SystImmune: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Trastuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 3Urothelial CancerDec 2028
BL-M05D1–Phase 1Gastric AdenocarcinomaFeb 2027
BL-M14D1–Phase 1Small Cell Lung Cancer Metastatic or Locally AdvancedDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07021066BL-M05D1Phase 1Gastric AdenocarcinomaOncologyFeb 2027
NCT07080242BL-M14D1Phase 1Small Cell Lung Cancer Metastatic or Locally AdvancedOncologyDec 2027
NCT07869836TrastuzumabPhase 3Urothelial CancerOncologyDec 2028

Targets

ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Pfizer Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Yuhan

Companies built like this

DualityBio Aston Sci. Chengdu SciMount Pharmatech Shanghai Miracogen Nuvalent

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.